Clinical Oncology
Volume 22, Issue 2 , Pages 119-124 , March 2010

Primary Radiotherapy for Carcinoma of the Retromolar Trigone: A Useful Alternative to Surgery

  • N.A. Bayman

      Affiliations

    • Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
    • Corresponding Author InformationAuthor for correspondence: N.A. Bayman, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 6HX, UK. Tel: +44-161-446-3337.
    • ,
  • A.J. Sykes

      Affiliations

    • Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
    • ,
  • S. Bonington

      Affiliations

    • Department of Radiology, The Christie NHS Foundation Trust, Manchester, UK
    • ,
  • T. Blackburn

      Affiliations

    • Department of Maxillofacial Surgery, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
    • ,
  • M. Patel

      Affiliations

    • Department of Maxillofacial Surgery, South Manchester University Hospitals NHS Foundation Trust, Manchester, UK
    • ,
  • R. Swindell

      Affiliations

    • Department of Medical Statistics, The Christie NHS Foundation Trust, Manchester, UK
    • ,
  • N.J. Slevin

      Affiliations

    • Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK

Received 6 August 2009 ,Revised 28 September 2009 ,Accepted 13 October 2009.

References 

  1. Genden EM, Ferlito A, Shaha AR, et al. Management of cancer of the retromolar trigone. Oral Oncol. 2003;39:633–637
  2. Byers RM, Anderson B, Schwarz EA, et al. Treatment of squamous carcinoma of the retromolar trigone. Am J Clin Oncol. 1984;7:647–652
  3. Antoniades K, Lazaridis N, Vahtsevanos K, et al. Treatment of squamous cell carcinoma of the anterior faucial pillar-retromolar trigone. Oral Oncol. 2003;39:680–686
  4. Lo K, Fletcher GH, Byers RM, et al. Results of irradiation in the squamous cell carcinomas of the anterior faucial pillar-retromolar trigone. Int J Radiat Oncol Biol Phys. 1987;13:969–974
  5. Barbosa JF. Cancer of the retromolar area; a study of twenty-eight cases with the presentation of a new surgical technique for their treatment. Arch Otolaryngol. 1959;69:19–30
  6. Hao SP, Tsang NM, Chang KP, et al. Treatment of squamous cell carcinoma of the retromolar trigone. Laryngoscope. 2006;116:916–920
  7. Kowalski LP, Hashimoto I, Magrin J. End results of 114 extended “commando” operations for retromolar trigone carcinoma. Am J Surg. 1993;166:374–379
  8. Mendenhall WM, Morris CG, Amdur RJ, et al. Retromolar trigone squamous cell carcinoma treated with radiotherapy alone or combined with surgery. Cancer. 2005;103:2320–2325
  9. Binahmed A, Nason RW, Abdoh AA, et al. Population-based study of treatment outcomes in squamous cell carcinoma of the retromolar trigone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:662–665
  10. Goldie SJ, Soutar DS, Shaw-Dunn J. The effect of surgical resection in the region of the retromolar trigone. J Plast Reconstr Aesthet Surg. 2006;59:1263–1268
  11. Huang CJ, Chao KS, Tsai J, et al. Cancer of retromolar trigone: long-term radiation therapy outcome. Head Neck. 2001;23:758–763
  12. Ayad T, Gelinas M, Guertin L, et al. Retromolar trigone carcinoma treated by primary radiation therapy: an alternative to the primary surgical approach. Arch Otolaryngol Head Neck Surg. 2005;131:576–582
  13. Cosentino D, Lazzati M. Results of radiotherapy of carcinomas of the retromolar trigone observed at the Varese Regional Hospital, Radiol Med (Torino). 1988;76:83–86
  14. Janot F, Klijanienko J, Russo A, et al. Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer. 1996;73:531–538
  15. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  16. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23:457–467
  17. Hendry JH, Bentzen SM, Dale RG, et al. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol (R Coll Radiol). 1996;8:297–307
  18. Hendry JH, Mackay RI, Roberts SA, et al. Outstanding issues in radiation dose-fractionation studies. Int J Radiat Biol. 1998;73:383–394
  19. Roberts SA, Hendry JH. The delay before onset of accelerated tumour cell repopulation during radiotherapy: a direct maximum-likelihood analysis of a collection of worldwide tumour-control data. Radiother Oncol. 1993;29:69–74
  20. Roberts SA, Hendry JH, Brewster AE, et al. The influence of radiotherapy treatment time on the control of laryngeal cancer: a direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor. Br J Radiol. 1994;67:790–794
  21. Slevin NJ, Hendry JH, Roberts SA, et al. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy. Radiother Oncol. 1992;24:215–220
  22. Dische S, Saunders M, Barrett A, et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123–136
  23. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933–940
  24. Withers HR, Peters LJ, Taylor JM, et al. Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: patterns of fractionation study of radiobiology. Int J Radiat Oncol Biol Phys. 1995;33:563–568
  25. Wiernik G, Alcock CJ, Bates TD, et al. Final report on the second British Institute of Radiology fractionation study: short versus long overall treatment times for radiotherapy of carcinoma of the laryngo-pharynx. Br J Radiol. 1991;64:232–241
  26. Turner SL, Slevin NJ, Gupta NK, et al. Radical external beam radiotherapy for 333 squamous carcinomas of the oral cavity – evaluation of late morbidity and a watch policy for the clinically negative neck. Radiother Oncol. 1996;41:21–29
  27. Ben-David MA, Diamante M, Radawski JD, et al. Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys. 2007;68:396–402
  28. Huang K, Xia P, Chuang C, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer. 2008;113:497–507
  29. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949–955
  30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578

PII: S0936-6555(09)00370-7

doi: 10.1016/j.clon.2009.10.017

Clinical Oncology
Volume 22, Issue 2 , Pages 119-124 , March 2010

Article Tools

* Image Usage & Resolution